Its key therapeutic areas include treatments for epilepsy, Parkinson's disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. 

Operating across Europe, North America, and Asia-Pacific, UCB has a significant presence in over 40 countries, delivering therapies to patients worldwide. 

In August 2024, UCB announced the sale of its Chinese neurology and allergy business to Singapore-based CBC and Abu Dhabi's Mubadala for $680 million. This strategic move enabled UCB to concentrate on launching novel medicines in immunology, neurology, and rare diseases within China. 

Additionally, in November 2024, UCB completed the sale of rights to two established brands, Atarax and Nootropil, for Europe and selected countries in Latin America and Asia-Pacific to ADVANZ PHARMA.